MERCURY-1 was multicenter, double-masked studies randomizing 718 patients 1:1:1 to FDC netarsudil/latanoprost, netarsudil 0.02% (Rhopressa, Aerie Pharmaceuticals), or latanoprost 0.005%. All medications were applied as a single drop once daily in the evening.
Eligible patients had bilateral open-angle glaucoma or ocular hypertension and an unmedicated IOP after washout of existing IOP-lowering medications of >20 mm Hg to <36 mm Hg at 8 a.m. during 2 qualification visits and >17 mm Hg to <36 mm Hg at 10 a.m. and 4 p.m. at the second qualification visit. The 3 treatment groups were well-balanced for their baseline demographic characteristics.
Patients returned for follow-up at weeks 2 and 6 and months 3, 6, 9, and 12. The primary efficacy endpoint was mean IOP at 8 a.m., 10 a.m., and 4 p.m. at week 2, week 6, and month 3, and the primary safety endpoint was adverse events during the 12-month study.
MERCURY-1 was designed as a superiority trial and it met its primary efficacy endpoint with FDC netarsudil/latanoprost demonstrating significantly greater IOP-lowering than both of its components at week 2, week 6, and month 3. Compared with both control groups and across all 3 timepoints, the treatment difference favoring the FDC group ranged from 1 mm Hg to 3 mm Hg.